$10M Invokana Lawsuit Seeks to Link Drug to Dire Side Effect Complications

April 25, 2016 – – TheProductLawyers.com reports on the lawsuit against the makers of Invokana, Janssen Pharmaceuticals (a branch of Johnson and Johnson Corporation), filed by a Texas resident in late 2015. The plaintiff links her use of the drug for management of type-2 diabetes to her development of diabetic ketoacidosis and other injuries suffered shortly after beginning a treatment regimen. The case was filed in U.S. District Court of New Jersey, and seeks damages and compensation for related past and future medical expenses in the amount of $10 million dollars.

Invokana and other drugs of this type belong to a class of drugs known as SGLT2 class inhibitors. They assist individuals with type-2 diabetes in managing blood glucose levels by diverting a portion of glucose directly to the kidneys. This sugar is blocked from reabsorption and eliminated via urination. While the Texas woman initially began taking Invokana as prescribed by her physician in October of 2013, she quickly began experiencing less than optimal results. Although SGLT2 class inhibitors have been extremely successful in accomplishing their purported function, they may also be connected to severe stress on the renal system and other complications.

In November of 2013, tests showed that she had sustained severe damage to her kidneys and was in a state of diabetic ketoacidosis (DKA). This condition is typically associated with type-1 diabetes, but can occur in cases of type-2 individuals. Essentially, the root is insufficient insulin in the bloodstream to process the glucose. Fat is then released from fat cells, absorbed by the liver, and the kidneys produce toxic acids called ketones, which build up in the blood.

In the two years since its FDA approval, Invokana has been associated with adverse event reports citing a connection to renal failure, DKA, and other conditions of kidney damage. The U.S. FDA is reviewing these reports and stresses a need for heightened awareness of potential impacts associated with SGLT2 class inhibitor drugs. They have issued summary warnings indicating the purported connection.

For more information about the Invokana lawsuits, or this press release, please contact TheProductLawyers.com on 888-997-3792.

###

Contact TheProductLawyers.com:

Banville Law
888-997-3792
info@banvillelaw.com
165 West End Ave #1h,
New York, NY 10023

ReleaseID: 60009501